Vericel (VCEL) Cash & Current Investments (2010 - 2026)
Vericel (VCEL) reported Cash & Current Investments of $145.3 million for Q1 2026, up 28.74% on a YoY basis from $112.9 million in Q1 2025, and up 5.71% sequentially from $137.5 million in Q4 2025.
Vericel (VCEL) Cash & Current Investments (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 15 years of Cash & Current Investments data on file, last reported at $145.3 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 28.74% year-over-year to $145.3 million; the trailing twelve-month figure through Mar 2026 stood at $145.3 million (up 28.74% YoY), and the FY2025 full-year result was $137.5 million, up 61.67% from the prior year.
- Cash & Current Investments advanced to $145.3 million in Q1 2026, from $137.5 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $145.3 million in Q1 2026 to a low of $70.4 million in Q3 2024.
- A 5-year average of $106.4 million and a median of $110.6 million in 2024 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments decreased 27.33% in 2023 and jumped 92.43% in 2025, its largest moves.
- Tracing VCEL's Cash & Current Investments over 5 years: stood at $119.5 million in 2022, then dropped by 27.33% to $86.9 million in 2023, then decreased by 2.09% to $85.0 million in 2024, then soared by 61.67% to $137.5 million in 2025, then advanced by 5.71% to $145.3 million in 2026.
- Business Quant data shows VCEL's Cash & Current Investments at $145.3 million in Q1 2026, $137.5 million in Q4 2025, and $135.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | - |
| 10 | Vericel | 2.34 Bn | 2.19 Bn | 49.27 Mn | 145.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 145.35 Mn |
| Dec 31, 2025 | 137.50 Mn |
| Sep 30, 2025 | 135.38 Mn |
| Jun 30, 2025 | 116.85 Mn |
| Mar 31, 2025 | 112.90 Mn |
| Dec 31, 2024 | 85.05 Mn |
| Sep 30, 2024 | 70.35 Mn |
| Jun 30, 2024 | 75.85 Mn |
| Mar 31, 2024 | 110.65 Mn |
| Dec 31, 2023 | 86.87 Mn |
| Sep 30, 2023 | 83.56 Mn |
| Jun 30, 2023 | 97.83 Mn |
| Mar 31, 2023 | 119.28 Mn |
| Dec 31, 2022 | 119.54 Mn |
| Sep 30, 2022 | 110.94 Mn |
| Jun 30, 2022 | 100.69 Mn |
| Mar 31, 2022 | 100.55 Mn |
| Dec 31, 2021 | 103.40 Mn |
| Sep 30, 2021 | 98.29 Mn |
| Jun 30, 2021 | 90.98 Mn |